ストックスクリーナーアプリを入手
25.83
2.01%
0.51
アフターアワーズ：
26.05
0.22
+0.85%
前日終値:
$25.32
開ける：
$25.76
24時間の取引高:
2.39M
Relative Volume:
1.06
時価総額：
$2.55B
収益：
$669.43M
当期純損益:
$-609.36M
株価収益率:
-4.2302
EPS:
-6.1061
ネットキャッシュフロー:
$-507.20M
1週間 パフォーマンス:
-2.49%
1か月 パフォーマンス:
-9.75%
6か月 パフォーマンス:
+13.69%
1年 パフォーマンス:
-12.50%
1日の値動き範囲:
$25.69
$26.75
1週間の範囲:
$24.97
$28.50
52週間の値動き範囲:
$18.29
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
25.83 | 2.50B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | ダウングレード | Goldman | Buy → Neutral |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy - Stocktwits
Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade) - Seeking Alpha
RARE Maintained by Morgan Stanley -- Price Target Raised to $74 - GuruFocus
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
How Investors May Respond To Ultragenyx Pharmaceutical (RARE) First FDA Accelerated Approval For GENGLYCOS - simplywall.st
182,638 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Blue Owl Capital Holdings LP - MarketBeat
RTW INVESTMENTS, LP Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shares Look 44% Undervalued on GF Value - GuruFocus
RARE Maintained by Canaccord Genuity -- Price Target Raised to $83 - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx scores FDA approval for gene therapy made at Bedford facility - The Business Journals
RARE Maintained by Citigroup -- Price Target Raised to $58.00 - GuruFocus
Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease - MedCity News
Ultragenyx Shares Surge as FDA Grants First-Ever Approval for GSDIa Gene Therapy - finance.biggo.com
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing - PharmTech.com
RARE Maintained by Wells Fargo -- Price Target Raised to $46.00 - GuruFocus
Ultragenyx, after setbacks, nabs first gene therapy approval - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company - MarketBeat
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - BioPharm International
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade - MarketBeat
Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa - pharmaphorum
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - TradingView
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double - insights.citeline.com
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million. - The Business Journals
H.C. Wainwright reiterates Ultragenyx stock rating at buy By Investing.com - Investing.com Nigeria
FDA approves Ultragenyx gene therapy - STAT
Canaccord raises Ultragenyx stock price target on FDA approval By Investing.com - Investing.com South Africa
Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock - Yahoo Finance
Ultragenyx Nabs FDA Nod for First Gene TherapyUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating at buy - Investing.com
Canaccord raises Ultragenyx stock price target on FDA approval - Investing.com
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy - Pharmaceutical Business review -
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy - MarketBeat
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $103 - GuruFocus
Ultragenyx’ Genglycos wins FDA accelerated approval - The Pharma Letter
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia - AllSci
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx stock surges on FDA gene therapy approval - Investing.com
Ultragenyx’s gene therapy wins first FDA approval for rare metabolic disorder - 101 WIXX
Ultragenyx Earnings Call Signals Record Sales, 2027 Pivot - TipRanks
Ultragenyx gets its first gene therapy over the regulatory finish line - FirstWord Pharma
RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher - Stocktwits
Ultragenyx receives FDA approval for gene therapy treating GSDIa By Investing.com - Investing.com Nigeria
Form 8K Ultragenyx For: 19 August By Investing.com - Investing.com South Africa
Ultragenyx stock surges on FDA gene therapy approval By Investing.com - Investing.com Australia
Ultragenyx’s gene therapy for rare metabolic disorder secures US FDA nod - 1470 & 100.3 WMBD
RARE Looks 41.8% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):